Quantité totale PI	54
Rang # Quantité totale PI	25 743
Note d'activité PI	2,6/5.0    55
Rang # Activité PI	13 259
Symbole boursier	HOWL (nasdaq)
ISIN	US95075A1079
Capitalisation	80.20M  (USD)
Classe Nice dominante	Services scientifiques, technolo...

Brevets Marques 24 3 11 0 15 0 1
Dernier brevet	2025 - Activatable interleukin 12 polyp...
Premier brevet	2019 - Activatable cytokine polypeptide...
Dernière marque	2020 - WEREWOLF
Première marque	2019 - WEREWOLF

Industrie (Classification de Nice)

Derniers inventions, produits et services 2025 Invention Activatable interleukin 12 polypeptides and methods of use thereof. The disclosure features fusi... 2024 Invention Activatable il-21 polypeptides and methods of use thereof and single domain human serum albumin a... Invention Enhanced adoptive cell therapy. The disclosure relates to combination therapy comprising an induc... Invention Activatable il-10 polypeptides and methods of use thereof. Provided herein are IL-10 prodrugs com... Invention Activatable cytokine polypeptides and methods of use thereof. The disclosure features fusion pro... Invention Il-12 prodrugs, methods of use and pharmaceutical compositions. This disclosure relates to method... Invention Il-2 prodrug. This disclosure relates to methods and compositions for treating cancer using an i... Invention Inducible il-2 and pd-1/pd-l1 combination therapy. This disclosure relates to methods and compos... Invention Inducible cytokine prodrug and pd-1/pd-l1 combination therapy. This disclosure relates to method... Invention Activatable interferon polypeptides and methods of use thereof. Provided herein are IFN polypept... 2023 Invention Separation moieties and methods of use thereof. Provided herein are separation moieties that are... Invention Il-12 prodrugs. This disclosure relates to methods and compositions for treating cancer using an ... Invention Activatable cytokine polypeptides and methods of use thereof. The disclosure features fusion prot... 2022 Invention Activatable il-12 polypeptides and methods of use thereof. Provided herein are IL-12 polypeptide... Invention Activatable interleukin-2 polypeptides and methods of use thereof. The disclosure features fusio... Invention Il-2 prodrug. This disclosure relates to methods and compositions for treating cancer using an in... Invention Activatable inteferon polypeptides and methods of use thereof. Provided herein are IFN polypeptid... Invention Inducible cytokine prodrug and pd-1/pd-l1 combination therapy. Prodrugs typically include a nativ... Invention Inducible il-2 and pd-1/pd-l1 combination therapy. This disclosure relates to methods and composi... Invention Activatable interleukin 12 polypeptides and methods of use thereof. The disclosure features fusio... Invention Separation moieties and methods of use thereof. Provided herein are separation moieties that are ... 2021 Invention Activatable interleukin-2 polypeptides and methods of use thereof. The disclosure features fusion... Invention Activatable il-12 polypeptides and methods of use thereof. Provided herein are IL-12 polypeptide ... 2020 P/S Pharmaceutical preparations for the diagnosis and/or treatment of cancer and immunological diseas... Invention Separation moieties and methods and use thereof. Provided herein are separation moieties that are... 2019 P/S Research and development of pharmaceuticals for the diagnosis and/or treatment of cancer and immu... Invention Activatable interleukin-2 polypeptides. The disclosure features fusion proteins that are conditio... Invention Activatable interleukin 12 polypeptides. The disclosure features fusion proteins that are conditi...